PMID- 25388240
OWN - NLM
STAT- MEDLINE
DCOM- 20160323
LR  - 20221207
IS  - 1865-8652 (Electronic)
IS  - 0741-238X (Linking)
VI  - 31
IP  - 11
DP  - 2014 Nov
TI  - Liraglutide for the treatment of type 2 diabetes mellitus: a meta-analysis of 
      randomized placebo-controlled trials.
PG  - 1182-95
LID - 10.1007/s12325-014-0164-2 [doi]
AB  - INTRODUCTION: Liraglutide has been widely used in the treatment of type 2 
      diabetes mellitus (T2DM), however, the results of a number of randomized 
      placebo-controlled trials on the effects of liraglutide for the treatment of T2DM 
      have varied. The purpose of this study was to assess the effects of liraglutide 
      versus placebo for the treatment of T2DM. METHODS: We searched randomized 
      controlled trials comparing liraglutide and placebo for the treatment of T2DM in 
      the following databases: MEDLINE; EMBASE; Cochrane Library Central Register of 
      Controlled Trials; and Clinical Trials Gov (through August 2014). The standard 
      mean difference (SMD) was calculated for the continuous data and a chi (2) test was 
      used to evaluate heterogeneity. RESULTS: Initially, 103 articles were retrieved 
      through the literature search and 11 studies met the requirements for the 
      meta-analysis. The effects of liraglutide on lowering glycosylated hemoglobin, 
      fasting plasma glucose, reducing weight, lowering blood pressure, and the 
      prevalence of adverse events were significantly different from placebo 
      (P < 0.0001, SMD = -0.96, 95% CI = [-1.20, -0.73]; P < 0.0001, SMD = -0.72, 95% 
      CI = [-0.99, -0.45]; P = 0.004, SMD = -0.24, 95% CI = [-0.40, -0.07]; P = 0.021, 
      SMD = -0.15, 95% CI = [-0.27, -0.02], and P = 0.007, respectively). CONCLUSION: 
      Liraglutide had greater hypoglycemic, weight-reducing and systolic blood 
      pressure-lowering effects than placebo. However, there were more adverse events 
      in the treatment with liraglutide. It is suggested that additional well-designed, 
      large, studies be conducted to further support the use of liraglutide and provide 
      objective guidance for clinical application of liraglutide.
FAU - Du, Qiang
AU  - Du Q
AD  - Department of Endocrinology, Shengjing Hospital of China Medical University, 
      Shenyang, 110004, China, kobe9903@sina.com.
FAU - Wang, Yan-Jun
AU  - Wang YJ
FAU - Yang, Sheng
AU  - Yang S
FAU - Zhao, Yue-Yang
AU  - Zhao YY
FAU - Han, Ping
AU  - Han P
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20141112
PL  - United States
TA  - Adv Ther
JT  - Advances in therapy
JID - 8611864
RN  - 0 (Glucagon-Like Peptide-2 Receptor)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 839I73S42A (Liraglutide)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
MH  - Blood Pressure/drug effects
MH  - Diabetes Mellitus, Type 2/diagnosis/drug therapy
MH  - Glucagon-Like Peptide 1/*analogs & derivatives
MH  - Glucagon-Like Peptide-2 Receptor/*agonists
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/adverse effects
MH  - *Liraglutide/administration & dosage/adverse effects
MH  - Outcome Assessment, Health Care
MH  - Randomized Controlled Trials as Topic
MH  - Weight Loss/drug effects
EDAT- 2014/11/13 06:00
MHDA- 2016/03/24 06:00
CRDT- 2014/11/13 06:00
PHST- 2014/10/08 00:00 [received]
PHST- 2014/11/13 06:00 [entrez]
PHST- 2014/11/13 06:00 [pubmed]
PHST- 2016/03/24 06:00 [medline]
AID - 10.1007/s12325-014-0164-2 [doi]
PST - ppublish
SO  - Adv Ther. 2014 Nov;31(11):1182-95. doi: 10.1007/s12325-014-0164-2. Epub 2014 Nov 
      12.